fda glp-1 warning 2025 november Receptor Agonists and vision risk fda glp-1 warning news november

That means patients must either have type 2 diabetes or fit into a rare exception category to receive these medications through Medicaid

Avoid repeated freeze-thaw cyclesaliquot if necessary

Conversely, those with inadequate response (less than 5% weight loss after 12-16 weeks at therapeutic doses) should discontinue per FDA labeling

Understand renewal requirements: If approved, know when your benefits expire and how to reapply to avoid any gaps in coverage

Senior Principal Research Fellow, SAHMRI GPs are increasingly being approached by patients inquiring about the use of peptides other than incretin-based therapies

Its essential to discuss these potential risks with your healthcare provider